Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherBEHAVIORAL PHARMACOLOGY

Compensatory Sleep Responses to Wakefulness Induced by the Dopamine Autoreceptor Antagonist (−)DS121

M. Foster Olive, Wesley F. Seidel and Dale M. Edgar
Journal of Pharmacology and Experimental Therapeutics June 1998, 285 (3) 1073-1083;
M. Foster Olive
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wesley F. Seidel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dale M. Edgar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The effect of the dopamine autoreceptor antagonist (−)DS121 on wakefulness, locomotor activity, body temperature and subsequent compensatory sleep responses was examined in the rat. Animals entrained to a light-dark cycle were treated at 5 h after lights-on (CT-5) with 0.5, 1, 5 or 10 mg/kg i.p. (−)DS121 or methylcellulose vehicle. An additional group received 5 mg/kg i.p. (−)DS121 or vehicle 6 h after lights-off (CT-18). At CT-5, (−)DS121 dose-dependently increased wakefulness, locomotor activity and body temperature, and decreased both non-rapid eye movement sleep (NREM) and rapid eye movement sleep (REM) during the first 4 h post-treatment relative to vehicle controls. REM interference lasted up to 3 h longer than NREM. Low doses of (−)DS121 (0.5 and 1 mg/kg) produced relatively little waking that was not followed by significant compensatory sleep responses. In contrast, higher doses (5 and 10 mg/kg) produced compensatory hypersomnolence (robust increases in NREM immediately after the primary waking effect) that was proportional to the duration of drug-induced wakefulness. NREM recovery 24 h post-treatment was the same for the 5 mg/kg (65.4 ± 9.9 min) and 10 mg/kg (64.8 ± 9.3 min) doses, but was not proportional to prior wake duration. NREM displaced by drug-induced wakefulness was recovered completely by 24 h post-treatment at the 5 mg/kg dose, but only 63.5% recovered at 10 mg/kg. In contrast, equivalent wakefulness produced by sleep deprivation yielded 100% NREM recovery. At CT-18, (−)DS121 (5 mg/kg) increased wakefulness without disproportionately increasing locomotor activity, and was compensated fully by 24 h post-treatment. These data show that (−)DS121 dose-dependently increases wakefulness, which is followed by hypersomnolence that is proportional to drug-induced wake-promoting efficacy.

Footnotes

  • Send reprint requests to: Dale M. Edgar, Ph.D., Sleep and Circadian Neurobiology Laboratory, Sleep Research Center, Stanford University School of Medicine, 701 Welch Road, Suite 2226, Palo Alto, CA 94304.

  • ↵1 Research supported by AG11084, AFOSR grant F49620–95-1–0388 and a grant from the Upjohn Company.

  • Abbreviations:
    ANOVA
    analysis of variance
    AP
    anterior-posterior
    ASBL
    average sleep bout length
    AWBL
    average wake bout length, CT, circadian time
    DAA
    dopamine autoreceptor antagonist
    DRINK
    drinking activity
    (−)DS121
    S(−)-3-(1-propyl-3-piperidinyl)-benzonitrile hydrochloride
    EEG
    electroencephalogram
    EMG
    electromyogram
    LMA
    locomotor activity
    LMAI
    locomotor activity intensity
    ML
    medial-lateral
    MSBL
    maximum sleep bout length
    MWBL
    maximum wake bout length
    NREM
    non-rapid eye movement sleep
    REM
    rapid eye movement sleep (paradoxical sleep)
    Tb
    body temperature
    WAKE
    wakefulness
    • Received October 13, 1997.
    • Accepted February 16, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 285, Issue 3
1 Jun 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Compensatory Sleep Responses to Wakefulness Induced by the Dopamine Autoreceptor Antagonist (−)DS121
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherBEHAVIORAL PHARMACOLOGY

Compensatory Sleep Responses to Wakefulness Induced by the Dopamine Autoreceptor Antagonist (−)DS121

M. Foster Olive, Wesley F. Seidel and Dale M. Edgar
Journal of Pharmacology and Experimental Therapeutics June 1, 1998, 285 (3) 1073-1083;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherBEHAVIORAL PHARMACOLOGY

Compensatory Sleep Responses to Wakefulness Induced by the Dopamine Autoreceptor Antagonist (−)DS121

M. Foster Olive, Wesley F. Seidel and Dale M. Edgar
Journal of Pharmacology and Experimental Therapeutics June 1, 1998, 285 (3) 1073-1083;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Daily Methocinnamox and Fentanyl Self-Administration
  • Abuse Potential of Botanical Cannabidiol
  • Efficacy as a Determinant of Hyperlocomotion by MOR Ligands
Show more Behavioral Pharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics